Abstract (248 words)
Many malignant human tumors, including melanomas are auxotrophic for arginine due to reduced expression of argininosuccinate synthetase1 (ASS1), the rate-limiting enzyme for arginine biosynthesis. Pegylated arginine deiminase (ADI-PEG20), which degrades extracellular arginine resulting in arginine deprivation, has shown favorable results in clinical trials for treating arginine-auxotrophic tumors. Drug resistance is the major obstacle for effective ADI-PEG20 usage. To elucidate mechanisms of resistance, 
Introduction
The amino acid L-arginine has many physiological functions because it is a precursor for the biosyntheses of proteins, nitric oxide, polyamines, proline, glutamate, creatine and agmatine. It also plays important roles in immune response to antigen by impaired cytokine production and an arrest in T cell proliferation (1, 2) . Arginine is primarily synthesized by 2 sequential enzymatic reactions in the urea cycle: argininosuccinate synthetase -1 (ASS1), which catalyzes the reaction of L-citrulline and aspartic acid to argininosuccinate, and argininosuccinate lyase (ASL) which recycles argininosuccinate back to arginine with the production of fumaric acid, an intermediate in the tricarboxylic acid (TCA) cycle (Fig. 1 ).
Many advanced human tumors, including melanomas, renal cell carcinomas, hepatocellular carcinomas, mesotheliomas, prostate cancers, and small cell lung cancers do not express ASS1 (3). ASS1-negative tumor cells therefore require arginine from the circulation for survival, whereas normal cells that synthesize arginine endogenously will survive under arginine deprivation conditions. Arginine deiminase (ADI) (4-7) and human arginase I (4, 8, 9) two arginine-depleting recombinant proteins ( Fig. 1) , have been under clinical development for treating arginine-auxotrophic tumors. ADI is produced by Mycoplasma spp. and humans do not produce this enzyme. Like most recombinant bacterial proteins, it is immunogenic and has a short half-life in vivo. Pegylated ADI (ADI-PEG20) has been formulated for clinical use. Clinical trials using ADI-PEG20 for treating various cancers including melanoma have produced favorable results (5, 6) .
Drug resistance remains an important contributor for the treatment failure, owing to re-expression of the once-silenced ASS1. Using a cultured melanoma cell system, we previously demonstrated that transcriptional regulation of ASS1 by ADI-PEG20 involves a and SK-Mel-2 cells that were continuously exposed to ADI-PEG20 with stepwise increases in concentrations, starting from 0.1 µg/mL and 0.05 µg/mL for A2058 and SKMel-2, respectively. Independent ADI R cell lines were established from single cells using 96-well-plate. Increased resistance in these clones were further developed by increased drug concentrations with 0.025 μg/mL increments for over 6 months, at which time the resistant cells were able to survive at 0.9 μg/mL of ADI-PEG20. Cells were routinely maintained at 0.3 μg/mL of ADI-PEG20.
Materials and Methods

Reagents
Glucose uptake
Glucose transport was measured according to the procedure described (13) . In 
Other procedures
Western blotting, chromatin immunoprecipitation (ChIP), cytotoxicity assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylthiazolium bromide (MTT) were performed as described previously (10, 11) .
Statistical Analyses
The IC 50 values were obtained from nonlinear regression analysis of levels than did the SK-Mel-2-R3 and SK-Mel-2-R4 lines (Fig. 2D ). Reduced expression of ASS1 in the SK-Mel-2-R1 and SK-Mel-2-R2 cell lines was correlated with less resistance to ADI-PEG20 (Fig. 2B ). These observations, together with our previous finding that modulation of ASS1 levels affects cell sensitivity to ADI-PEG20 (4, 10), strongly support that ASS1 expression is the predominant mechanism for acquired resistance to ADI-PEG20 in cultured melanoma cells. (Fig. 3A, left) . However, no suppression of ASS1 expression was found in A2058-R1, A2058-R2 and SK-Mel-2-R3, except SK-Mel-2-R1 cells (Fig. 3A, right) We also performed ChIP assay to determine the occupancy of HIF-1α and c-Myc at the ASS1 promoter. Consistent with our previous results (10), we found that HIF-1α, but not c-Myc, binds to the ASS1 promoter in the parental A2058 (Fig. 3C, lane 1) and SK-Mel-2 cells (Fig. 3D, lane 1) . In contrast, in all the ADI (Fig. 4A) . Activation of AKT-1 in these ADI R cells was reflected by increased sensitivities to the killing by LY294002 and perifosine which inhibit PI3K and AKT1 activities, respectively (Fig. 4B ).
Roles of c-
Downregulated mTOR signaling in ADI R
Cell Lines
Three well-characterized sensing mechanisms for cellular amino acid and/or nutritional deprivation in eukaryotic cells include the mammalian target of rapamycin complex 1 (mTORC1), general amino acid control nonderepressible 2 (GCN2) and AMP-dependent protein kinase (AMPK) (18, 19) . mTORC1 phosphorylates and 
activates protein kinase p70S6 kinase 1 (S6K1) which subsequently activates mRNA cap binding by phosphorylating eIF-4B for the formation of translational initiation complex. GCN2 is the only kinase for eukaryotic initiation factor 2α (eIF2α) that senses the absence of one or more amino acids by virtual of direct binding to uncharged cognate tRNA (20) . Phosphorylation of elF2α (p-eIF2α) by activated GCN2 prevents the assembly of eIF2-GTP-Met-tRNA 
We then investigated whether ADI-PEG20 resistance would alter the metabolic programs. Because ASL is directly downstream from ASS1 in the urea cycle (Fig. 1) , we performed Western blotting of its expression in 5 ADI R -A2058 lines. We found that ASL expression levels were elevated in all 5 ADI R cell lines (Fig. 5A) . (Fig. 1) , but lower levels of PDH (Fig. 5A) . PDH is the key enzyme that catalyzes the conversion of pyruvate into acetyl CoA, an important metabolic intermediate in the TCA cycle (Fig. 1) .
Monocarboxylate transporter family (MCT, SLC16) catalyzes the rapid transport across the plasma membrane of many monocarboxylates including lactate (25) . Since these ADIR cells show elevated expression of LDH-A, we examined the expression levels of MCT1 and MCT4 in ADI R A2058 cells. Results showed that levels of MCT1 were increased in A2058-R1, A2058-R2, A2058-R4, and A2058-R5, but reduced in A2058-R3; whereas levels of MCT4 were increased in A2058-R2, A2058-R3, and A2058-R5, but reduced in A2058-R4, and no change in A2058-R1 (data not shown). 
ADI R cells exhibit elevated glutaminolytic metabolism and increased sensitivity to glutaminase Inhibitors
Two key enzymes in glutaminolytic metabolism, glutaminase (GLS) and glutamine dehydrogenase (GDH), catalyze the 2-step sequential conversion of glutamine into α-ketoglutarate via glutamate intermediate (Fig. 1) . Mammals express 2 These results indicate that induction of ASS1, Glut1, LDH-A, occurred very early during the development of ADI resistance, and elevation of GDH levels occurred subsequently (Fig. 6A) .
GLS isoforms, kidney-type (or GLS1) and liver-type (GLS2). GLS1 is expressed in
Since elevated expression of ASS1 is the principal mechanism of ADI resistance, we investigated whether enhanced expression of these enzymes was the consequence of ASS1 upregulation in the ADI R cell lines. To this end, we used transfection to establish 2 independently overexpressed ASS1 cell lines in A2058 and A375 cells.
While no apparent alteration of HIF-1α levels was discernible even using prolonged exposure of the Western blots (not shown). We found that expression of c-Myc, Glut1, LDH-A, GLS1 and GDH was reduced (Fig. 6B ). This expression profile is directly opposite from that in the ADI an important transcription regulator of 10% to 20% of total cellular genes through E-box interactions in mammalian cells (31, 32) . A2058-R1 and A2058-R2 cells were treated with 2 independent c-Myc shRNA for 48 hr. Although the shRNA we used could only partially reduce c-Myc levels, we found reduced expression of Glut1 and GLS1 in these ADI R cells as compared with those in the scramble shRNA-treated controls, whereas levels of LDH-A and GDH were not affected. The inability of reducing LDH-A and GDH suggest that either other mechanisms are involved for the regulation of LDH-A and GDH or regulation of these enzymes by c-Myc is more stringent than Glut1 or GLS1. In any event, these results support that c-Myc plays a role in regulating metabolic rewiring during the development of ADI-PEG20 resistance.
Expression of enzymes involved in the lipid biosynthesis in the ADI
R cell lines
We also determined the expression of enzymes involved in fatty acid 
Discussion
The discovery that many human malignant tumors do not express ASS1 and are arginine-auxotrophic provides a mechanistic basis for using recombinant argininedepleting enzymes in targeted therapy of these diseases (4) . We found that these ADI R variants exhibited elevated AKT signaling and are preferentially sensitive to PI3K/AKT inhibitors. These findings support the important role of this pathway in ADI-PEG20 resistance (11) . We also observed that expression of mTOR and its downstream signal p70S6K was downregulated in all ADI R cells. While the canonical pathway of mTOR regulation is through the PI3K/AKT pathway (33), however, downregulation of mTOR independent of this pathway has also been reported (34) . The molecular mechanism for downregulation of mTOR signal in ADI resistance remains to be investigated.
We further demonstrated that ASL was elevated in these ADI 
deprivation conditions. Our results are consistent with recent findings that several enzymes in the urea cycle may be co-regulated (37), including ASS1, ASL, nitric oxide synthetase, and cationic amino acid transporter 1 and may form a supermolecular complex to perform important physiological function (38) .
We found that these ADI R cells have altered metabolic program toward aerobic glycolysis by enhancing Glut1 and LDH-A expression but reducing PDH expression, exhibiting the Warburg phenomenon. Since Warburg's work in 1929, it has been evidenced that cancer cells, even under aerobic conditions, frequently upregulate glucose metabolism leading to a high uptake and use of glucose, but a moderate rate of mitochondrial respiration (39, 40) . This characteristic has led to the development of 2- We also discovered that elevated expression of ASS1 by transfection downregulates Glut1, LDH-A, GLS1, and GDH expression, demonstrating that modulating ASS1 levels can influence the expression of other enzymes in distance, i.e. glycolytic and glutaminolytic pathways. While the precise mechanism(s) remain to be investigated, downregulation of c-Myc may be responsible for the reduced expression of these enzymes in these ASS1-treansfected cells, although this remain to be elucidated. 
